[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemiplegia-and-hemiparesis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemiplegia-and-hemiparesis":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,62,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":38,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100597086","phase-1-psychedelic-healing-adjunct-therapy-harnessing-opened-malleability-100597086",false,"NCT07053917","Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability","PHATHOM","Inclusion Criteria:\n\n* Over age 18 years, inclusive.\n* Ischemic or hemorrhagic stroke confirmed by CT or MRI, at least 12 months prior to admission date\n* Ability to give informed consent and understand the tasks involved.\n* Agree that, for the study duration, will refrain from: (1) No new prescription medications during the time of the study without approval of the study team, (2) taking any herbal supplement (except with prior approval of the research team), (3) taking any nonprescription medications with the exception of: 1. non-steroidal anti-inflammatory drugs. 2. acetaminophen. 3. vitamins. 4. or other over-the-counter medications approved by the research team\n* Are willing to follow restrictions and guidelines concerning medications, consumption of food, beverages, and nicotine the night before and just prior to psilocybin administration.\n* Agree to have transportation other than driving themselves home or to where the participants are staying after the administration of psilocybin.\n* Are willing to be contacted via telephone for all necessary telephone contacts.\n* Must have a negative pregnancy test if able to bear children.\n* Must provide a contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal.\n* Must agree to inform the investigators within 48 hours of any new medical conditions and procedures.\n* Are proficient in speaking and reading English.\n* Agree to have all clinical visit sessions recorded to audio and video.\n* Agree to not participate in any other interventional clinical trials during the duration of this study.\n\nExclusion Criteria:\n\n* Taking one of the following medications in the 30 days prior to psilocybin administration:\n\n  1. selective serotonin reuptake inhibitor (SSRI)\n  2. Serotonin-norepinephrine reuptake inhibitors (SNRI)\n  3. Buproprion\n  4. Valproic acid\n  5. Zolpidem\n  6. Trazodone\n  7. Carbamazepine.\n  8. tricyclic antidepressants\n  9. Monoamine Oxidase Inhibitors\n  10. Mirtazapine\n\n  l. Lithium m. Buspirone n. Atypical antipsychotics o. Zolpidem p.Carbamazepine q. Clonazepam r. Gabapentin s. Lamotrigine t. Levetiracetam u. Phenobarbital v. Phenytoin w. Topiramate x. Valproic Acid y. Zonisamide\n* History of medically significant suicide attempt.\n* Evidence of acute cardiac dysfunction as evidenced by either elevated troponin or EKG changes within 48 hours of administration.\n* Systolic blood pressure that is greater than 150 mmHg systolic on \\> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.\n* Diastolic blood pressure that is greater than 100 mmHg systolic on \\> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.\n* Systolic blood pressure is less than 90 mmHg systolic on \\> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.\n* Diastolic blood pressure is less than 30 mmHg systolic on \\> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.\n* Systolic blood pressure exceeds 160 mmHg or is less than 90 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.\n* Diastolic blood pressure exceeds 100 mmHg or is less than 30 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.\n* Cognitive impairment that, in the estimation of the study team, would preclude the use of the MindPod Dolphin.\n* History of physical or neurological condition that interferes with study procedures or assessment of motor function (e.g. severe arthritis, severe neuropathy, Parkinson's disease).\n* Social and\u002For personal circumstances that interfere with ability to perform follow up assessments.\n* Are pregnant or nursing.\n* Weigh less than 48 kg.\n* Are not able to give adequate informed consent.\n* Are actively abusing opioids, cocaine, Phencyclidine (PCP), amphetamines, or alcohol.\n* Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID-5) criteria for moderate or severe substance use disorder\n* Diagnosis of schizophrenia, history of prior psychosis, anxiety requiring hospitalization, or Type 1 bipolar.\n* Hypernatremia\n* Hypokalemia (but can have received repletion during the prior 24 hours)\n* Hyperkalemia\n* Glomerular filtration rate of \\\u003C 30 ml\u002Fmin\n* Elevated of white blood cell count\n* Hemoglobin \\\u003C 7 g\u002Fdl\n* Platelet count \\\u003C 100,000 g\u002Fdl\n* Acute cardiac dysfunction demonstrated by either troponin elevation (chronic elevation is acceptable), or EKG changes suggestive of acute coronary syndrome.\n* Active suicidal ideation as assess by the C-SSRS.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.",[26,27,28,29,30,31,32,33,34,35,36,37],"Stroke","Chronic Stroke","Intracerebral Haemorrhage","Intracerebral Haemorrhage (ICH)","Intracerebral Hemorrhage Basal Ganglia","Ischemic Stroke","Ischemic Stroke and Hemorrhagic Stroke","Hemiparesis After Stroke","Hemiplegia Following Ischemic Stroke","Hemiplegia and Hemiparesis","Hemiplegia and\u002For Hemiparesis Following Stroke","Middle Cerebral Artery Stroke",[39,40,41,42,43,44,45,46,47,48],"psychedelic","stroke","chronic stroke","intracerebral hemorrhage","stroke recovery","motor recovery","poststroke recovery","poststroke motor recovery","hemiparesis recovery","psychedelic safety","RECRUITING","2026-02-11",{"date":52,"type":53},"2026-02-13","ACTUAL",{"date":55,"type":53},"2026-02-09",{"date":57,"type":20},"2027-03",{"name":59,"class":60},"Johns Hopkins University","OTHER",1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100584193","spinal-stimulation-and-gait-training-to-improve-mobility-in-tbi-100584193","NCT06886152","Spinal Stimulation and Gait Training to Improve Mobility in TBI","Transcutaneous Spinal Stimulation and Gait Training to Improve Mobility and Motor Control in Individuals With Traumatic Brain Injury","DOD SS","Inclusion Criteria:\n\n* Have weakness on at least one side of my body.\n* No injury to my unaffected side in 6 months.\n* Be cleared by a physician to participate in this study.\n* Have had a non-penetrating TBI at least 2 years ago. A non-penetrating injury is an injury where my skull remained closed and no object entered it.\n* Have enough strength to use a hemiwalker or walker.\n* Be between 18-65 years of age.\n* Be medically stable for at least 6 months before enrolling. This means that I have not had an emergency room visit, hospitalization, or medical procedure (such as a surgery) during this period of time.\n* Able to walk 10 yards with minimal assistance without an ankle-foot orthosis (brace)\n* Able to respond to and tolerate surface stimulation, as determined by study staff\n* Have the ability to communicate in English.\n* Have stable blood pressure.\n* Be willing and able to give informed consent.\n* Be able and willing to comply with study procedures, verbal instructions, and follow-up requirements.\n\nExclusion Criteria:\n\n* Have must have not had physical or occupational therapy or treatment for a balance disorder within 30 days prior to study enrollment. I must not participate in physical or occupation therapy throughout the duration of the study to avoid affecting the study results.\n* Have any medical issues that affect my unaffected side (such arthritis, fracture, etc.).\n* Have skin issues that would prevent me from being able to use the surface stimulation (such as a open wound or rash).\n* Have a pre-existing condition that may make it difficult for me to participate in exercise. (uncontrolled hypertension as described by a physician, heart disease, abnormal heart rate or rhythm, or congestive heart failure).\n* Have been hospitalized for heart attack, heart surgery or acute heart failure within 3 months of enrollment in study.\n* Have an implanted medical or metallic device.\n* Reduced sensation in my lower limbs and stimulation locations.\n* Have Botox injections in my legs up to 3 months prior to enrolling.\n* Have physical therapy for walking.\n* Have uncontrolled seizure disorder (such as epilepsy)\n* Have nervous system-related issues (for example Parkinson's disease, multiple sclerosis).\n* Major changes to my medications throughout the study\n* Have bone or muscle issues unrelated to traumatic brain injury that interfere with my walking or limit my range of motion in my legs.\n* Be currently pregnant. Because of potential risk to the fetus, women of child bearing potential will be required to have a pregnancy test before they can enroll in this study. If I am female, and have a positive pregnancy test, I will not be enrolled.\n* Have any other medical conditions that my doctor or physical therapist feels would affect my ability to use the stimulation or participate in walking training TMS Specific - Exclusion (those with these exclusions can still participate in other parts of the study)\n* I have a history of seizure disorder or have a close family member (parent, brother, sister, or child) who has a seizure disorder.\n* I have had unexplained fainting spells.\n* I have had an active migraine headaches.\n* I have a past or current history of ringing in the ears (tinnitus) or severe hearing problems.\n* I am currently taking or withdrawing from any medication that would increase my risk of seizure (determination made in consultation with study physician).\n* I have a history of alcohol or drug abuse in the prior 3 years.\n* I have nerve damage outside of my brain or spinal cord (such as in an arm or leg).\n* I am unwilling to participate in TMS.","65 Years",{"count":72,"type":20},30,[74],"NA","The purpose of this research study is to assess the effects of receiving transcutaneous spinal stimulation while performing walking exercises compared to completing walking exercises without spinal stimulation for individuals with hemiplegic TBI.",[77,78,35],"Traumatic Brain Injury","Traumatic Brain Injury (TBI)","NOT_YET_RECRUITING","2025-08-25",{"date":82,"type":53},"2025-09-02",{"date":84,"type":20},"2025-09-01",{"date":86,"type":20},"2028-09-01",{"name":88,"class":60},"Kessler Foundation",2,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":89},"100597250","the-efficacy-of-additional-motor-training-dosage-during-the-early-stages-post-stroke-on-the-upper-extremity-recovery-100597250","NCT07056049","The Efficacy of Additional Motor Training Dosage During the Early Stages Post Stroke on the Upper Extremity Recovery","Efficacy of High-dosage, High-intensity Rehabilitation Program on the Motor Recovery After Stroke in Subacute Patients","EFODIN","Inclusion Criteria:\n\n* Age ≥18 years\n* Ischemic or hemorrhagic stroke (hemispheric or brainstem) confirmed by CT or MRI\n* First-ever stroke or previous stroke with no upper extremity weakness\n* 1 week ≤ Time after stroke onset ≤ 6 weeks\n* Active shoulder flexion of at least 20◦ and partial wrist and\u002For finger active movement\n* Ability to provide inform consent\n\nExclusion Criteria:\n\n* A painful shoulder limiting an active forward reach\n* Severe spasticity or non-neural loss of range of motion\n* Cognitive or communication impairments as determined by the clinical team Unstable medical conditions",{"count":99,"type":20},50,[74],"Intervention abstract\n\nBackground: Stroke is the leading cause of long-term disability, and the second leading cause of death in the western world. Most stroke survivors will suffer from motor and cognitive disturbances for the rest of their life, which negatively affects their normal daily life.\n\nDespite the decline in stroke-related mortality over the past decades, the outcome of rehabilitation programs does not improve, and is predictable regardless of the program used. Still, several human and animal studies show that high capacity of training in the early stages post stroke improve motor recovery. This notion is far from being well established.\n\nAim: Studying the effect of high-dosage, high-intensity training program in the subacute period on upper extremity motor recovery.\n\nPopulation: Stroke survivors. Study duration: 6 months. Study protocol: Participants will receive additional technology-based upper extremity training for 120 min\u002Fday, 5d\u002Fw, 4 weeks. They will be monitored pre and post training, and 6 months post-stroke. Outcome measures will include clinical, kinematic and adherence measures (see complete list in the protocol).",[26,35],[104,105,106,107,108],"Stroke Rehabilitation","Motor Impairment","Post-stroke High Dosage Rehab","Technological Rehab Post Stroke","Stroke Kinematics","2025-07-14",{"date":111,"type":53},"2025-07-17",{"date":113,"type":53},"2025-07-13",{"date":115,"type":20},"2027-07-15",{"name":117,"class":60},"Adi Negev-Nahalat Eran"]